These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 33864145)
1. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145 [TBL] [Abstract][Full Text] [Related]
2. Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors. Rachner TD; Göbel A; Jaschke NP; Hofbauer LC J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32674135 [TBL] [Abstract][Full Text] [Related]
3. Management of bone loss due to endocrine therapy during cancer treatment. Khan MI Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss. Gaudio A; Xourafa A; Rapisarda R; Castellino P Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654 [TBL] [Abstract][Full Text] [Related]
5. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer. Chukir T; Liu Y; Farooki A Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446 [TBL] [Abstract][Full Text] [Related]
6. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer. Ito K; Blinder VS; Elkin EB J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313 [TBL] [Abstract][Full Text] [Related]
8. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML; Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857 [TBL] [Abstract][Full Text] [Related]
9. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Hadji P; Aapro MS; Body JJ; Bundred NJ; Brufsky A; Coleman RE; Gnant M; Guise T; Lipton A Ann Oncol; 2011 Dec; 22(12):2546-2555. PubMed ID: 21415233 [TBL] [Abstract][Full Text] [Related]
10. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)]. Takahashi S Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031 [TBL] [Abstract][Full Text] [Related]
11. The role of bisphosphonates in the adjuvant setting for breast cancer. Reeder JG; Brufsky AM Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with bone-targeted agents. Wilson C; Coleman RE Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355 [TBL] [Abstract][Full Text] [Related]
13. Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience. Tremblay D; Patel V; Fifer KM; Caro J; Kolodka O; Mandelli J; Shapiro CL Support Care Cancer; 2018 Jan; 26(1):197-202. PubMed ID: 28744736 [TBL] [Abstract][Full Text] [Related]
14. Cancer-treatment-induced bone loss, part 2. Michaud LB; Goodin S Am J Health Syst Pharm; 2006 Mar; 63(6):534-46. PubMed ID: 16522890 [TBL] [Abstract][Full Text] [Related]
15. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary. Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede HJ Med J Aust; 2019 Sep; 211(5):224-229. PubMed ID: 31318068 [TBL] [Abstract][Full Text] [Related]
16. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Brufsky A Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF; Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499 [TBL] [Abstract][Full Text] [Related]
18. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850 [TBL] [Abstract][Full Text] [Related]
19. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648 [TBL] [Abstract][Full Text] [Related]
20. Osteoporosis management in patients with breast cancer: EMAS position statement. Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]